BioCentury
ARTICLE | Company News

FDA approves GE's AdreView

September 20, 2008 2:05 AM UTC

FDA approved an NDA from General Electric (NYSE:GE) for AdreView as a molecular imaging agent to detect neuroendocrine tumors. The company plans to launch the iobenguane I 123 injection, which has Orp...